INTRODUCTION AND HYPOTHESIS: The purpose of this study is to assess the validity of patient goal achievement in overactive bladder (OAB). METHODS: Data were taken from a placebo-controlled randomised trial of transdermal oxybutynin and open label extension study. Face validity was assessed using qualitative analysis. Convergent validity was assessed by comparison with objective symptom improvement. Responsiveness was assessed at 4 s, using the standardised effect size. Reliability was assessed between 4 and 12 weeks of treatment. RESULTS:Ninety-six women were randomised. There were moderate correlations (0.50-0.51) between goal achievement and symptom improvement for urinary urgency and urge incontinence. Mean goal achievement demonstrated good reliability (intraclass correlation = 0.82) but low responsiveness (r = 0.14) between transdermal oxybutynin and placebo-treated groups. CONCLUSIONS: Although patient goals have good face validity and can be reliably measured, they have limited convergence with conventional measures of OAB severity and improvement and low responsiveness.
RCT Entities:
INTRODUCTION AND HYPOTHESIS: The purpose of this study is to assess the validity of patient goal achievement in overactive bladder (OAB). METHODS: Data were taken from a placebo-controlled randomised trial of transdermal oxybutynin and open label extension study. Face validity was assessed using qualitative analysis. Convergent validity was assessed by comparison with objective symptom improvement. Responsiveness was assessed at 4 s, using the standardised effect size. Reliability was assessed between 4 and 12 weeks of treatment. RESULTS: Ninety-six women were randomised. There were moderate correlations (0.50-0.51) between goal achievement and symptom improvement for urinary urgency and urge incontinence. Mean goal achievement demonstrated good reliability (intraclass correlation = 0.82) but low responsiveness (r = 0.14) between transdermal oxybutynin and placebo-treated groups. CONCLUSIONS: Although patient goals have good face validity and can be reliably measured, they have limited convergence with conventional measures of OAB severity and improvement and low responsiveness.
Authors: Christopher R Chapple; Walter Artibani; Linda D Cardozo; David Castro-Diaz; Michael Craggs; Francois Haab; Vik Khullar; Eboo Versi Journal: BJU Int Date: 2005-02 Impact factor: 5.588
Authors: Lior Lowenstein; Kimberly Kenton; Kristen Pierce; Mary P Fitzgerald; Elizabeth R Mueller; Linda Brubaker Journal: Am J Obstet Gynecol Date: 2007-12 Impact factor: 8.661
Authors: Eman A Elkadry; Kimberly S Kenton; Mary P FitzGerald; Susan Shott; Linda Brubaker Journal: Am J Obstet Gynecol Date: 2003-12 Impact factor: 8.661
Authors: Sangeeta T Mahajan; Eman A Elkadry; Kimberly S Kenton; Susan Shott; Linda Brubaker Journal: Am J Obstet Gynecol Date: 2006-03 Impact factor: 8.661
Authors: Ethan M Balk; Gaelen P Adam; Katherine Corsi; Amanda Mogul; Thomas A Trikalinos; Peter C Jeppson Journal: J Gen Intern Med Date: 2019-05-06 Impact factor: 5.128